Page 9 of 32 · 745 questions tagged clinical-trials.
This came up because two published schedules for the same agent differ. I would like help reading this properly rather than being told what conclusion to reach. I…
Details up front: dizziness · tirzepatide · SURPASS-3. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at…
The specifics, since they change the answer: FLOW · 2 mg. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am…
I have three data points across nine months, which I hope is enough to see a trend. I can parse the result. I am less sure what it licenses me to conclude. I have…
Setup, so nobody has to ask: PIONEER-1 · fatigue · 7 mg. I would like help reading this properly rather than being told what conclusion to reach. I have the full…
Concretely: FLOW · vomiting. I have read the primary source rather than the summary, which has left me with more questions. I understand the headline. I do not…
The label documentation for the agent in question is ambiguous on exactly this point. I have read the primary source rather than the summary, which has left me with…
Conditions: 15 mg · tirzepatide. The failure mode I am trying to avoid is making this decision emotionally. I have twelve months in view and I would like the plan to…
Setup, so nobody has to ask: SUSTAIN-6 · 2.4 mg. I have read the primary source rather than the summary, which has left me with more questions. I understand the…
I am asking mechanistically rather than practically — I want the model, not the protocol. This is presented as though it settles something, and I am not convinced it…
What I am working with: SOUL · a GLP-1 receptor agonist. This is asserted often enough that I assumed it was established, and then I went looking for the source. I…
Details up front: ATTAIN-1 · orforglipron. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to…
The particulars: 0.5 mg · ecnoglutide. I am at the decision point and I would rather think it through than improvise. I would rather spend money on measurement than…
Details up front: PIONEER-1 · oral semaglutide. I am asking for verification rather than opinion, ideally with something I can read myself. It is possible the…
Numbers first: a GLP-1 receptor agonist · 25 °C. I am asking for verification rather than opinion, ideally with something I can read myself. It is possible the…
I am asking about the pattern rather than about my own management, which is elsewhere. I am asking for verification rather than opinion, ideally with something I can…
Details up front: vomiting · tirzepatide · SURMOUNT-1. This is presented as though it settles something, and I am not convinced it does. I have two documents that…
The specifics, since they change the answer: STEP 3 · early satiety. I want to understand what this actually establishes, as opposed to what it is being used to…
Details up front: mazdutide · 4 °C. I would rather be corrected now than propagate something wrong. I am specifically not interested in a testimonial; I am interested…
Conditions: oral semaglutide · tirzepatide. The comparison I want does not seem to exist anywhere in a form I can evaluate. I have read the arguments for each and…
Details up front: cagrilintide · 30 °C. I would rather be corrected now than propagate something wrong. I am specifically not interested in a testimonial; I am…
Conditions: TRIUMPH-3 · 8 mg. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the specifics change the…
What I am working with: constipation · cagrilintide · REDEFINE-1. I would like help reading this properly rather than being told what conclusion to reach. I have the…
Concretely: TRIUMPH-1 · fatigue. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the specifics change…